Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of MEDI7183 in Moderate to Severe Ulcerative Colitis (Japan)
jRCT2080222367Phase 2
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abrilumab in autoimmune colitis (4 arms), sponsored by AstraZeneca.
02
Drugs
abrilumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080222367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222367.